TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04017429

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement with osteoplasty
Description: Treatment of furcation grade III defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the tooth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement with osteoplasty
Description: Treatment of furcation grade III defect with open flap debridement followed by osteoplasty treatment. Osteoplasty includes altering the bone buccal to the furcation opening to \>90 degrees relative to the apico-coronal axis of the tooth.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement without osteoplasty
Description: Treatment of furcation grade III defect with open flap debridement only.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open flap debridement without osteoplasty
Description: Treatment of furcation grade III defect with open flap debridement only.
Study: NCT03232320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meditoxin
Description: Meditoxin (Botulinum toxin type A)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (Normal saline)
Study: NCT00710684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-742457 15mg
Description: SB-742457 - 15mg added to existing donepezil treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-742457 35mg
Description: SB-742457 - 35mg added to existing donepezil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo added to existing donepezil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: donepezil 5-10mg
Description: existing donepezil treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil 5-10mg
Description: existing donepezil treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil 5-10mg
Description: existing donepezil treatment
Study: NCT02620241

Intervention type: OTHER
Group type: OTHER
Intervention: sitting position
Study: NCT04443621

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: Questionnaire battery for assessment of dignity, cognition, self-sufficiency, and depression.

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: Questionnaire battery for assessment of dignity, cognition, self-sufficiency, and depression.

Intervention type: BEHAVIORAL
Intervention: in-depth interview
Description: Individual in-depth interviews with OAwD on the topic of dignity (two interviews with each respondent at a 12-month interval) .
Study: NCT01479686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iMRI
Description: 3.0TiMRI guided resection in adults with glioma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional neuronavigation
Description: conventional neuronavigation guided resection in adults with glioma
Study: NCT03765762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRF6019
Description: GRF6019 for IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for IV infusion
Study: NCT00255658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03043222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroLift as artifical device for prostatic urethral lift.
Description: UroLift as artifical device for prostatic urethral lift. The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroLift as artifical device for prostatic urethral lift.
Description: UroLift as artifical device for prostatic urethral lift. The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embospheres Microspheres as embolic agents for prostate artery embolization
Description: Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate. The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embospheres Microspheres as embolic agents for prostate artery embolization
Description: Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate. The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
Study: NCT01077362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab 45 mg
Description: SC injections
Study: NCT02868619

Intervention type: OTHER
Group type: OTHER
Intervention: ADO-BEDS scale
Description: Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria

Intervention type: OTHER
Group type: OTHER
Intervention: R-CMAS scale
Description: Evaluate the anxiety
Study: NCT01077362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab 90 mg
Description: SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ustekinumab 90 mg
Description: SC injections
Study: NCT04758221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment by composite coronal build-up
Description: A total of (42) decayed or traumatized primary anterior teeth were treated with composite coronal build-up based on the micromechanical adhesive procedure of composite resin in addition to macro mechanical retentive grooves created on the lateral sides of the cervical one third of the roots of treated teeth.
Study: NCT03307915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Participants will receive Ad26.Mos4.HIV 5\*10\^10 vp as 0.5 mL IM injection at Weeks 0, 12 in Group 1 and at Weeks 0, 12, 24, 36 in Group 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Participants will receive Ad26.Mos4.HIV 5\*10\^10 vp as 0.5 mL IM injection at Weeks 0, 12 in Group 1 and at Weeks 0, 12, 24, 36 in Group 2.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-Mosaic
Description: Participants will receive MVA-Mosaic 10\^8 pfu as IM injection at Weeks 24 and 36.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C gp140 + Mosaic gp140
Description: Participants will receive both Clade C gp140 125 mcg plus Mosaic gp140 125 mcg (250 mcg coformulated with Aluminum phosphate adjuvant) OR an equivalent dose of a bivalent vaccine that includes both Clade C gp140 and Mosaic gp140, and aluminum phosphate adjuvant in a single vial, via IM injection at Weeks 24 and 36.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
Study: NCT02868619

Intervention type: OTHER
Group type: OTHER
Intervention: R-CMAS scale
Description: Evaluate the anxiety
Study: NCT02077153

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminiscence therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active participation in group setting
Study: NCT01755247

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Gel Vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8% NVN1000 Topical Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 8% NVN1000 Topical Gel and moisturizer
Study: NCT03238456

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivating Pacifika Against Cigarettes and Tobacco
Description: Participants received one encouraging text message per day prior to their quit date. During the intervention, they received daily text messages with decreasing frequency per week. Participants were also able to craft personal text messages. On-demand text messages were optional and could be requested by texting key words to the program hotline.~The online MPACT program allowed participants to access eight educational modules and a forum where they could communicate with other participants. The modules focused on different aspects of quitting smoking, such as how to deal with withdrawal symptoms, triggers of tobacco use, and stress. Participants were limited to one module per day in order to increase the duration of exposure to the program. Upon completion, participants no longer received text messages but they were still able to access the educational modules, forum, and on-demand text messages.
Study: NCT02364505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine mindfulness-based intervention
Description: Comparison of telemedicine mindfulness intervention with telemedicine psycho-education control group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education intervention
Description: Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
Study: NCT05947708

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysate Flow Rate
Description: Hemodialysis is completed with dialysate being used at differing flow rates. Flow rates will be modified to see if this is a causal factor in post-dialysis recovery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysate Flow Rate
Description: Hemodialysis is completed with dialysate being used at differing flow rates. Flow rates will be modified to see if this is a causal factor in post-dialysis recovery.
Study: NCT04231747

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CC-97540
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540.~During CC 97540 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 97540 product, subjects will receive treatment with CC 97540 therapy.~Each cycle will include lymphodepleting chemotherapy followed by one dose of CC 97540 administered by intravenous (IV) injection.
Study: NCT04620122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Training and Music Therapy
Description: Progressive Muscle Relaxation Training and Music Therapy have applied to the participants two sessions for a week during two months.
Study: NCT01859221

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation
Description: Stereotactic radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation
Description: Stereotactic radiation
Study: NCT03292198

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 20-30 mmHg compression sleeve and gauntlet
Description: Compression garments are Juzo Soft, circular knit. Most will be off-the-shelf sizing, but custom when necessary.~Garment fittings will be performed by Certified Lymphedema Therapists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20-30 mmHg compression sleeve and gauntlet
Description: Compression garments are Juzo Soft, circular knit. Most will be off-the-shelf sizing, but custom when necessary.~Garment fittings will be performed by Certified Lymphedema Therapists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Description: Manual Lymphatic Drainage (MLD) is a gentle skin-stretch massage that stimulates the lymphatic system and assists in creating collateral drainage pathways out of non-intact (damaged) lymphatic territories. MLD is a critical part of Complete Decongestive Therapy (CDT), which is accepted as the international standard of care in the treatment of lymphedema.~The MLD sessions will be performed by 2 Certified Lymphedema Therapists, Megan Klote and Sarah Stolker, both trained through the Norton School of Lymphatic Therapy. The therapists have completed reliability meetings regarding MLD sequencing and techniques.
Study: NCT00123617

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phase III group-based cardiac rehabilitation
Description: Phase III group-based cardiac rehabilitation
Study: NCT02375880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: Administration by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: Administration by intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DKN-01
Description: Administration by intravenous (IV) infusion.
Study: NCT02612805

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined training
Description: Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic more resistance training.~Aerobic component (between 30 and 40 minutes of the sessions): Method: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.~Resistance component (Between 10 and 20 minutes of the sessions): Method: Multiple sets (2 to 4 sets of 30 to 15 seconds) in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: Maximum execution speed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training placebo
Description: Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Activities performed in main part: Stretching and relaxation in aquatic environment.
Study: NCT03659890

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low nucleotide
Description: 2 week, twice daily, supplementation with a nucleotide-depleted mycoprotein drink, with added dextrose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High nucleotide
Description: 2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added dextrose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High nucletide + Ribose
Description: 2 week, twice daily, supplementation with a nucleotide-rich mycoprotein drink, with added ribose
Study: NCT03721978

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: 1 milliliter (mL) VGX-3100 injected IM.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: 1 mL of matched Placebo injected IM.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CELLECTRA™-5PSP
Description: CELLECTRA™-5PSP used for EP following IM injection of VGX 3100.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™-5PSP
Description: CELLECTRA™-5PSP used for EP following IM injection of VGX 3100.
Study: NCT02459236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-301
Description: CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CERC-301
Description: CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
Study: NCT03179800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MobiusHD
Description: The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Implantation
Description: Sham Implantation
Study: NCT01971606

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.~A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.~B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.
Study: NCT03535584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Participants will be asked to complete 2 1-hour exercise sessions per week for 8 weeks (16 total sessions) under the supervision of a licensed respiratory therapist on non-dialysis days. The exercise program will be based on pulmonary rehabilitation and will follow guidelines established by the American Thoracic Society. Exercise sessions will include endurance (treadmill or cycle ergometer), strength (weight resistance), and flexibility training. Exercise sessions will be tailored to individual participants, and participant safety will be monitored during each session.
Study: NCT03619941

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Montmorency Tart Cherry Juice
Description: 100% natural, tart Montmorency cherry concentrate (30mL) diluted with 100mL water.~Concentrate contains no sweeteners, preservatives, flavourings or added sugar.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink attempted to match for total energy content, macronutrient content, appearance and taste of Montmorency tart cherry juice.
Study: NCT01034579

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Subjects who had received Rebif® 44 microgram (mcg) three times a week for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: Subjects who had received Copaxone® (Glatiramer Acetate) 20 milligram once daily for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
Study: NCT01763788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV
Study: NCT01190332

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: endoscopic sphincterotomy by conventional method

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic sphincterotomy by rendezvous method
Study: NCT00717678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prograf-XL
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: oral
Study: NCT01899274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bant iPhone application
Study: NCT01321398

Intervention type: OTHER
Intervention: Esophageal Pressure Monitoring
Description: An esophageal pressure monitor will be placed through the mouth into the esophagus by a study physician. Placement will be confirmed by a bedside chest X-ray. Once placement has been confirmed all air will be evacuated from the balloon by syringe. One ml of air will then be injected to partially inflate the esophageal balloon. Pleural pressure measurements will be recorded after 1 minute without spontaneous breathing or patient care related movement. This measurement will be repeated at 30 minutes and at 60 minutes after the first measurement. Trans-pulmonary pressure is calculated as the difference between esophageal pressure and mouth pressure. Once the measurements have been recorded, the catheter will be removed.
Study: NCT02459236

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo